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Background. Multiple myeloma (MM) is an hematologic tumor caused
by the accumulation of malignant plasma cells in the bone marrow
(BM). The dysregulated expression of two Notch ligands, Jagged1 and
Jagged2, hyperactivates the Notch pathway both in MM cells and in BM
stromal cell (BMSC). Several Notch downstream mediators are involved
in MM cell survival and proliferation, i.e. IL6, SDF1α, CXCR4, NF-kB,
VEGF and IGF. Although treatments with new drugs, such as alkylat-
ing agents, proteasome inhibitors and immunomodulatory agents,
increased patients’survival, MM remains incurable, principally due to
the development of endogenous or BM-mediated drug resistance (DR).
Therefore it is crucial to find new therapeutic targets. The aim of this
study was to investigate the role of Notch signaling in endogenous and
BMSC-promoted DR in MM. Materials and Methods. U266 and OPM2
cell lines were maintained in complete RPMI-1640 medium. The BMSC
lines NIH3T3 (murine) and HS5 (human) were maintained in complete
DMEM medium. MM cells were cultured alone or on a BMSC mono-
layer for 24h, and subsequently treated with Mitoxantrone, Borte-
zomib, Melphalan or the vehicle in the presence or the absence of the
CXCR4 antagonist AMD3100 for additional 24 hours. BMSCs were
previously stained with PKH26 (Sigma-Aldrich) to discriminate them
from MM by flow cytometry. Apoptosis was determined by Annexin
V-FITC staining. qRT-PCR reactions were carried out in a 7500 Fast
Real-time PCR system (Applied Biosystems) using the Maxima™ SYBR
Green/ROX qPCR Master Mix (ThermoScientific Inc) using murine or
human primer sets to discriminate the source of the RNA molecules.
Silencing of Jagged1 and 2 was obtained by transient expression of spe-
cific siRNAs. Results. The possible role of Notch withdrawal in DR was
investigated by silencing Jagged 1 and 2 ligands in MM cell lines OPM-
2 and U266. Results showed an increased sensitivity to Bortezomib,
Mitoxantrone and Melphalan associated to a decrease in the expression
of SDF1α, CXCR4, Bcl-XL, Bcl-2, Survivin and ABCC1. When co-cul-
tured with murine and human BMSCs, MM cells showed increased DR
due to: i) increased expression of anti-apoptotic genes in MM cells, i.e.
Bcl-XL, Bcl-2, Survivin and ABCC1; ii) BMSC release of soluble medi-
ators relevant to MM cells, i.e. SDF1α and VEGF. We suggest that these
effects may be driven by the reciprocal activation of Notch signaling
observed in both cell types and consistently we demonstrated that DR
may be significantly reduced by silencing Jagged1 and 2 in MM cells.
Finally, the evidence that CXCR4 blockade significantly reduced MM
cells resistance to Bortezomib induced by BMCSs, indicates that
CXCR4/SDF1α chemokine axis is a key mediator of Notch in MM-
associated DR. Conclusions. The evidence that Jagged1/2 silencing affects
endogenous and BMSC-induced DR in MM cells supports the use of a
Jagged-targeted approach in MM therapy alone or in combination with
common drugs.
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Efficacy and tolerance of bendamustine in combination with borte-
zomib-dexamethasone was evaluated in patients with relapsed and
refractory multiple myeloma (rrMM), whose prognosis is severe, so
that there is a strong need for new options for the management of these
patients. 24 patients, 13 males, 11 females, with rrMM, who had been
treated with a schedule Bendamustine-based, were retrospectively ana-
lyzed. Median age at diagnosis was 63.2 years (range 39-82) while age
at start of treatment was 66 years (range 48-83), and median number of
prior lines of treatment was 6.3 (range 4-8). ISS was equally distributed,
and cytogenetic characteristics were evaluable in 9 patients, only two
of whom had cytogenetic abnormalities, and in particular one of them
had del13q and in the other one was observed t(11;14). All the patients
had previously been treated with schedule containing bortezomib and
lenalidomide, while 90% of them had been treated with melphalan,
77% with cyclophosphamide and 34% with anthracyclines, and 30%
had also received radiotherapy. 58% of patients had undergone at least
to a single autologous stem cell transplantation. Last treatment before
bendamustine was a bortezomib-based regimen in 39%, an IMIDs-
based regimen in 49% (a combined bortezomib/IMIDs-based regimen
in 27%), while 12% of patients had received other chemotherapies. All
patients were relapsed and refractory to last therapies received. Only
patients completing at least two two courses of Bendamustine were
considered. A total of 87 cycles was administered (median 4.3, range 2-
9). In 91% of patients bendamustine was variously associated to borte-
zomib (66%), or IMIDs (25%) and only in 8% it was combined only
with dexametasone. In our schedule, Bendamustine was given, at a
median dose of 90 mg/sqm (range total dose: 120-180 mg) on day +1
and +2 every 28 days. After a median follow-up of 6.1 months, medi-
an OS from diagnosis was 57.3 months, while median OS from start of
Bendamustine was 6.7 months (range 2-19 months). 11/24 patients died
for progressive disease. 2/24 patients died for other causes (one for car-
diovascular disease and the other one had a gastric cancer). Grade 3
transfusion-dependent anemia occurred in 36% while in 53% grade 3
neutropenia occurred. We observed no severe extrahematologic toxic-
ity, only grade 1 gastrointestinal side effect (nausea), treated by common
antiemetic drugs. According to IMWG uniform response criteria, 15
out of 24 evaluable patients achieved a partial response after a median
time of 2.4 months with an overall response rate of 62.5%. In particu-
lar, for 3 patients of this study. In conclusion, Bendamustine has shown
significant efficacy in a particularly severe setting of patients, relapsed
and refractory to almost all available therapeutic resources, and in par-
ticular cases it could be considered as a bridge to a second autologous
or to allogeneic BMT.
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